UNSPSC 51314313: Ammonium chloride/chlorpheniramine/dextromethorphan/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE504. This VA Drug Class (RE504) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/EXPECTORANT.

UNSPSC 51314313 Ammonium chloride/chlorpheniramine/dextromethorphan/phenylephrine, a Commodity code, nominally covers a branded cough and cold medication, but recent state and local procurement activity under this code shows substantial mismatch. The opportunities posted involve naloxone procurement (Seminole County, Florida), direct-to-manufacturer pharmaceutical prescriptions (Texas HHS), and generic multi-source pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance). The code itself refers to a specific fixed combination, whereas the recent solicitations target broader pharmaceutical categories, generic equivalents, and specialty drug-deactivation systems. This divergence suggests the code may be used loosely by procurement offices to tag general pharmaceutical purchasing activity that does not align with the narrow commodity definition, or opportunities are mislabeled in the source system.

Issuing bodies include county health departments, state HHS commissions, and cooperative purchasing consortia spanning multiple states. Recent activity appears in Florida, Texas, and Minnesota, with the Minnesota MMCAP solicitation operating as a multi-state vehicle. Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023—note the date inconsistency in source) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. Texas HHS issued RFI HHS0017013 (posted April 3, 2026) to explore direct-to-manufacturer prescription programs without pharmacy benefit manager intermediaries. MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) seeks generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with contracts effective July 1, 2026. The code shows light recent activity with significant scope misalignment between the pharmaceutical commodity name and the actual work being procured.